Compare · ELMD vs MDT
ELMD vs MDT
Side-by-side comparison of Electromed Inc. (ELMD) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELMD and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $117.19B, about 525.6x ELMD ($223.0M).
- Over the past year, ELMD is up 7.3% and MDT is down 2.8% - ELMD leads by 10.1 points.
- MDT has been more active in the news (13 items in the past 4 weeks vs 7 for ELMD).
- MDT has more recent analyst coverage (25 ratings vs 3 for ELMD).
- Company
- Electromed Inc.
- Medtronic plc.
- Price
- $26.76-1.11%
- $91.64-0.28%
- Market cap
- $223.0M
- $117.19B
- 1M return
- -36.90%
- +1.06%
- 1Y return
- +7.34%
- -2.78%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- AMEX
- NYSE
- IPO
- 2011
- News (4w)
- 7
- 13
- Recent ratings
- 3
- 25
Electromed Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest ELMD
- Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event
- SEC Form 4 filed by Electromed Inc.
- SEC Form 4 filed by Electromed Inc.
- Electromed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-K filed by Electromed Inc.
- Electromed Announces CEO’s Planned Retirement
- Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results
- Electromed, Inc. to Report Q4 Fiscal 2026 Financial Results on August 25, 2026
- Chief Financial Officer Nagel Bradley M. covered exercise/tax liability with 674 shares, decreasing direct ownership by 3% to 18,964 units (SEC Form 4) (for tax liability)
- CEO and President Cunniff James L. exercised 9,700 shares at a strike of $17.25 and sold $354,095 worth of shares (9,700 units at $36.50) (SEC Form 4)
Latest MDT
- Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
- Medtronic executives to speak at upcoming investor conferences
- SEC Form 10-Q filed by Medtronic plc.
- SEC Form IRANNOTICE filed by Medtronic plc.
- Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance
- Medtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted Surgery
- Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR
- Needham reiterated coverage on Medtronic with a new price target
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 1,084 units of Ordinary Shares, decreasing direct ownership by 0.92% to 116,336 units (SEC Form 4)